InvestorsHub Logo
Followers 72
Posts 6896
Boards Moderated 0
Alias Born 12/07/2011

Re: None

Sunday, 09/24/2017 1:04:21 PM

Sunday, September 24, 2017 1:04:21 PM

Post# of 402814
I'll paint a picture: IPIX - Developing innovative drugs for unmet medical needs. They care about the science and never focus on the flash!

In the next 3-4 months: I expect the B-OM topline results to come out first and these results will trump all current drugs in development at the same stage and B-OM will become the first 'preventative' drug for OM on the market. These results will catapult the share price and possibly lead to a partnership by end of year.

As the B-OM buzz is fresh, they will release the Kevetrin phase 2 results for Ovarian Cancer and the results will be good. The results will be exactly what BP was looking for and the patients may see a good response in Tumor shrinkage in the 4th week. I believe Kevetrin will surprise the medical community and the investment community.

While we see unparalleled share price increases, we then are dropped with Prurisol phase 2b top line data in January and that data will blow the top off the share price. The data I suspect will crush Otezla's numbers.

I expect a collaboration by early next year and I expect this share price to be well over 20 dollars. JMO and my picture
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News